MOTS-c Before and After: What Changed in the Studies, and What a Person Can Actually Measure

Every MOTS-c before and after post has the same problem, which is that the compound's documented effects are the kind that do not photograph. It alters glucose handling, fat oxidation and, in animals, endurance. Nothing in the literature says it changes how a person looks, and the one placebo controlled trial of anything MOTS-c shaped found that the placebo group lost nearly as much liver fat as the treatment group did.

So this page does something different from the usual timeline of testimonials. It sets out what actually changed, before and after, in the studies that measured it, over what timespan and at what dose. It then lays out what a person could track that would register a real effect, and what the honest week by week expectation looks like when it is built from evidence rather than from posts. Research use only, and nothing here is a dosing recommendation. The dosage page has the reported protocols and the benefits page has the full evidence review.

Before and After in the Mouse Studies

The animal work is where the timelines come from, so it is worth being precise about what was measured and when. The doses are stated because they matter: everything below used between 0.5 and 15 mg per kilogram per day, which after body surface area scaling is twenty to a hundred times the reported human protocols. These are ceilings on how fast the biology can move, not forecasts for a 5 mg a week protocol.

Two patterns are worth pulling out. First, the metabolic changes were fast: a week of daily dosing was enough to move glucose tolerance and clamp sensitivity (Lee C et al., Cell Metab 2015;21:443, doi 10.1016/j.cmet.2015.02.009). Second, the performance and ageing effects needed either a high daily dose for two weeks or a long intermittent schedule over months (Reynolds JC et al., Nat Commun 2021;12:470, doi 10.1038/s41467-020-20790-0). Nothing in the mouse work looked at body composition in an animal that was already overweight, which is the before and after most people searching this term are hoping for.

Before and After in the One Human Trial

MOTS-c itself has not been through a controlled human trial. Its analog CB4211 has, in a phase 1a/1b study registered as NCT03998514 and completed in April 2021, and the phase 1b portion is the only real before and after data in people. Twenty obese adults with non alcoholic fatty liver disease were randomised to 25 mg once daily by subcutaneous injection or placebo for four weeks, eleven on drug and nine on placebo.

The liver fat row is the important one and it cuts both ways. The treatment did nothing that the placebo did not, which is disappointing for the compound. But the placebo arm lost almost five percentage points of liver fat in a month, which is what happens when people enrol in a trial, get weighed and scanned, and quietly start behaving better. That number is the single best explanation for why uncontrolled before and after reports look so good. The liver enzyme and glucose changes are real signals, small, from eleven people, with a molecule that is not the one sold to researchers.

Why It Will Not Show in a Photo

The documented mechanism is AMPK activation in skeletal muscle, which raises glucose uptake and shifts fuel use toward fat. In principle that could change body composition over a long enough period. In practice, no study has measured it in a person, and the effect size that would be needed to be visible in a photograph, several kilograms of fat over a couple of months, is larger than anything the animal data suggests at any dose people use. The site's general before and after page collects reader reports across compounds, and the MOTS-c section there describes modest composition shifts over twelve weeks; read those as reports, in the sense that they are what people said happened while they were also training and eating differently.

What MOTS-c might plausibly change, on the evidence, is a set of numbers: fasting glucose, insulin sensitivity, the heart rate at which a given pace feels hard, and how a fixed cardio effort feels in week six versus week one. Those are real outcomes. They are also the kind that a person who is expecting to see something in the mirror will conclude never happened.

What the Endogenous Data Says About Timing

There is one more source of before and after data, and it is the peptide the body makes itself. In the 2021 study, ten sedentary young men rode a stationary bicycle and their skeletal muscle MOTS-c rose 11.9-fold after the session, with circulating levels up 1.6-fold during and 1.5-fold after, and everything back to baseline within four hours of rest. That is a fast, large, transient response, and it says something about what an injected dose might be mimicking: a signal that spikes and clears, not a level that builds. The other endogenous pattern is the slow one. Circulating MOTS-c is lower in type 2 diabetes and in obese boys, and a 2023 review put levels in young adults 11% and 21% above middle aged and older adults respectively (Zheng Y et al., Front Endocrinol 2023, doi 10.3389/fendo.2023.1120533). Nobody has shown that injecting the peptide restores that age related decline in a person, or that restoring it would change anything you could measure at home.

One practical implication: a good share of the before and after posts that rank for this term are stacks. One of the posts ranking for this term at the time of writing is a retatrutide plus MOTS-c log, and retatrutide is a compound with phase 2 weight loss data measured in double digit percentages of body weight. In a stack like that, the visible change belongs to the incretin and MOTS-c is a passenger whose contribution nobody can separate out. If the post does not name every compound in the protocol, it is not a MOTS-c before and after.

What a Self Experiment Would Track

If the point of a before and after is to find out whether anything happened, measure the things the studies measured. This is a description of what a properly run self experiment looks like, not a recommendation to run one.

A self experiment would take the full set before the first dose, at four weeks, and at the end of the block, and would change nothing else during the block that could be avoided, because the placebo arm of the CB4211 trial is what happens when you do. The cycle length guide covers why blocks and breaks are convention for this compound rather than a mechanism driven requirement, and the side effects page covers what a log should catch.

A Week by Week Expectation Built From the Evidence

This is not a report of what happened to anyone. It is what the mechanism and the study timelines would predict, at the reported research doses, for a person tracking the markers above. Any single reader's experience will differ, and the honest prior for most of the rows is that nothing measurable happens at all.

The realistic before and after for MOTS-c, then, is a set of lab and fitness numbers that may move a little, a subjective sense of energy that may or may not be real, and a body that looks the same. Anyone whose goal is a visible change should be reading the weight loss peptides page, where the compounds have trial data with photographs' worth of effect size. Anyone whose goal is metabolic and who can measure it has a compound with a coherent mechanism, a good short term tolerability signal, and no human efficacy data. The peptides for energy comparison puts it next to SS-31 and NAD+ on that basis.

How to Read a Forum Before and After

• Ask what else changed. Almost every twelve week MOTS-c post also describes a training block, a diet, or a second compound started the same week. The cycle guide explains why single variable blocks are the only ones that tell you anything.
• Ask what was measured. A post with a fasting glucose and a resting heart rate before and after is worth ten with a mirror selfie.
• Remember the placebo arm. Nine people on placebo lost 4.88 points of liver fat in a month. Attention is a treatment.
• Check the sex of the poster against the data. The human genetic evidence and the mouse work both show MOTS-c doing less or nothing in females, so a result reported by a man is weaker evidence for a woman than it looks.
• Discount anything under four weeks. No study measured anything sooner in a person, and the mouse studies that moved fastest used doses nobody reports using.

Key Takeaways

• The documented MOTS-c effects are metabolic and invisible: glucose handling, insulin sensitivity, fat oxidation, endurance in old mice
• Mouse timelines ran from 7 days for glucose tolerance to 8 weeks for obesity prevention, at doses 20 to 100 times the reported human protocols
• The one human trial, of the analog CB4211, found lower ALT, AST and glucose at four weeks and no separation from placebo on liver fat
• The placebo group lost almost as much liver fat as the treated group, which is the best explanation for uncontrolled before and after reports
• A real before and after tracks fasting glucose, resting heart rate, a repeatable cardio test, waist and weight, taken at baseline, four weeks and end of block
• A visible body change is not predicted by any evidence at any reported dose
• Nothing persists after a break on any pharmacological reasoning available

Frequently Asked Questions

What does MOTS-c do before and after, realistically?

The effects with evidence behind them are metabolic and invisible: glucose handling, insulin sensitivity, fat oxidation and, in old mice, endurance. None of those shows in a mirror. A four week human trial of the analog CB4211 measured lower liver enzymes and glucose against placebo, a trend in weight, and no difference in liver fat. There is no controlled human data showing a body composition change from MOTS-c, and the before and after photos online are testimonials, not results.

How long does MOTS-c take to work?

In mice, glucose tolerance improved after seven days of daily dosing, running capacity after ten to fourteen days, and obesity prevention was measured over eight weeks. Those animals received doses far above anything reported in people, so the timelines are a ceiling on how fast the biology can move, not a prediction. In the human analog trial, the liver enzyme and glucose changes were measured at four weeks. Anyone judging a protocol before four weeks is judging an interval shorter than any study.

Does MOTS-c cause weight loss?

Not on any human evidence. Mice on a high fat diet that were given MOTS-c from day one did not become obese, at the same calorie intake as controls, but that is prevention rather than loss and nothing shows it reversing existing obesity. The CB4211 trial reported a trend toward lower body weight over four weeks that did not reach significance. The weight loss compounds with human trial data are the incretin peptides.

What should I track to see whether MOTS-c is doing anything?

The markers the studies used: fasting glucose and HbA1c, resting heart rate, a repeatable submaximal cardio test such as a fixed distance at a fixed heart rate, waist circumference and body weight on the same scale at the same time of day, each taken before starting and at four and eight weeks. Body fat by DEXA is better than a photograph, which will not capture a metabolic change at all.

Why do forum before and after posts look better than the studies?

Selection, timing and stacking. People who noticed nothing rarely post. The posts that do exist usually describe eight to twelve weeks that also included a diet change, a training block or a second compound, and MOTS-c gets the credit. The one placebo controlled trial found that the placebo group lost about as much liver fat as the treated group, which is what an uncontrolled four weeks of paying attention to your health does on its own.